Next-generation macrocyclic peptide therapeutics powered by the Synova™ platform
Syneron Bio is a Beijing-based biotech company dedicated to the development of next-generation macrocyclic peptide therapeutics, leveraging artificial intelligence and drug synthesis technology. The company has completed Series A, A+, and Series B financing rounds totaling approximately $400M, with backers including AstraZeneca. It operates in the intersection of AI and synthetic biology for drug discovery.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2026
Apr 2026
Dec 2025
Create a free account to see which investors have funded this company.
Create Free Account
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
